Autolus Therapeutics (AUTL) Liabilities and Shareholders Equity (2017 - 2025)
Autolus Therapeutics' Liabilities and Shareholders Equity history spans 9 years, with the latest figure at $589.1 million for Q4 2025.
- For Q4 2025, Liabilities and Shareholders Equity fell 24.74% year-over-year to $589.1 million; the TTM value through Dec 2025 reached $2.7 billion, down 19.22%, while the annual FY2025 figure was $589.1 million, 24.74% down from the prior year.
- Liabilities and Shareholders Equity reached $589.1 million in Q4 2025 per AUTL's latest filing, down from $661.9 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $901.4 million in Q1 2024 to a low of $263.8 million in Q3 2022.
- Average Liabilities and Shareholders Equity over 5 years is $565.5 million, with a median of $490.3 million recorded in 2022.
- Peak YoY movement for Liabilities and Shareholders Equity: soared 108.51% in 2024, then dropped 24.74% in 2025.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $405.6 million in 2021, then rose by 20.89% to $490.3 million in 2022, then decreased by 23.43% to $375.4 million in 2023, then surged by 108.51% to $782.7 million in 2024, then decreased by 24.74% to $589.1 million in 2025.
- Per Business Quant, the three most recent readings for AUTL's Liabilities and Shareholders Equity are $589.1 million (Q4 2025), $661.9 million (Q3 2025), and $721.0 million (Q2 2025).